Suicide/suicidal thoughts or clinical worsening
Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant relief of symptoms occurs. As improvement may not occur during the first weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempt and should receive be careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy, especially in early treatment and following dose changes. Patients (and carers) should be advised of the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour, and to seek medical advice immediately if these symptoms persist
Section 2 of the corresponding PIL should always contain the following information for patients:
This medicine may be associated with thoughts of self-harm and suicidal behaviour in some people.
Tell someone you trust, who can help you in an emergency, that you are taking this medicine and ask that they read this leaflet.
Talk to your trusted person, prescriber or go to a hospital straight away, if after starting this medicine, you have new or worse:
• Feelings of anxiety or irritability
• Feelings of restlessness and agitation
• Extreme increases in activity and difficulty sleeping
• Thoughts of acting on dangerous impulses to harm yourself
• Thoughts about suicide or dying
• Changes in behaviour or mood you, or someone you trust, notices and is worried about.
In some people, thoughts of self-harm and suicidal behaviour may be increased when first starting antidepressants. Antidepressants take time to work; and sometimes side effects occur before you or others notice improvements in your mood.
Never stop taking an antidepressant suddenly without first talking to a healthcare professional. Stopping an antidepressant medicine suddenly can cause other symptoms related to withdrawal to occur.
Information from clinical trials has shown the highest risk of thoughts of self harm and suicidal behaviour, is in adults aged less than 25 years who were treated with an antidepressant but the risk applies to people of all ages treated with these medicines.
Call NHS 111 who can offer you support, until you can be with someone who can help you in person.
In addition to the above text for section 2 of the PIL a headline should be at the top of the PIL in a box to contain the following information:
| Warning – Thoughts of self-harm and suicidal behaviour – see section 2 |
Elderly patients
When treating elderly patients, the daily dose should be increased more slowly, with regular monitoring of blood pressure. The administered daily doses should be kept as low as possible (see section 4.2).
Patients with renal impairment:
There is insufficient experience with tranylcypromine in the treatment of patients with impaired renal function. Therefore, patients with severe disorders of renal function should not be treated with tranylcypromine. Other patients with impaired renal function should be closely monitored (see section 4.2).
Use tranylcypromine with great caution in patients with cardiovascular disease in whom physical activity should be regulated, as the drug may supress angina pain.
Tyramine-rich food must not be consumed by patients on MAO inhibitor therapy, which is the cause of severe hypertensive reactions (see section 4.5 'Dietary precautions').
Use tranylcypromine with great caution in epileptic patients, as tranylcypromine has a variable effect on the convulsive threshold in animals.
Tranylcypromine may aggravate some co-existing symptoms in depression such as anxiety and agitation.
Tranylcypromine should preferably be withdrawn at least two weeks before elective surgery because of possible drug interactions.
It is not recommended for mild depressive states resulting from temporary situational difficulties.
Caution should be exercised in prescribing tranylcypromine for patients with a previous history of dependence on drugs or alcohol.
Tranylcypromine therapy should be withdrawn gradually.
This medicinal product contains lactose.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.